伊维菌素与安慰剂对轻中度COVID-19门诊患者持续恢复时间的影响:一项随机临床试验
ACTIV-6平台试验在美国93个站点纳入1591例30岁及以上、确诊COVID-19且急性感染症状持续7天以内的门诊患者,随机接受伊维菌素400 μg/kg每日1次连用3天(n=817)或安慰剂(n=774)。伊维菌素组与安慰剂组恢复时间改善的HR为1.07(95%CrI 0.96-1.17;后验P值[HR>1]=.91),中位恢复时间分别为12天与13天,第28天住院或死亡复合终点两组均为1.2%(HR 1.1,95%CrI 0.4-2.6)。结论认为伊维菌素未显著改善轻中度COVID-19门诊患者的恢复时间,这些发现不支持使用伊维菌素。
要点
- 伊维菌素400 μg/kg每日1次连用3天未显著缩短轻中度COVID-19门诊患者的持续恢复时间(HR 1.07,95%CrI 0.96-1.17)。
- 伊维菌素组中位恢复时间12天(IQR 11-13),安慰剂组13天(IQR 12-14)。
- 第28天住院或死亡复合终点两组均为1.2%(HR 1.1,95%CrI 0.4-2.6)。
核心结论
- 在轻中度COVID-19门诊患者中,与安慰剂相比,伊维菌素治疗未显著改善恢复时间,这些发现不支持在轻中度COVID-19患者中使用伊维菌素。
研究设计与样本
- ACTIV-6为正在进行的、去中心化、双盲、随机、安慰剂对照的平台试验,旨在评估轻中度COVID-19门诊患者的再利用疗法。
- 2021年6月23日至2022年2月4日从美国93个站点纳入1591例30岁及以上、确诊COVID-19且急性感染症状持续7天以内、有2种或以上症状的参与者,随访数据截至2022年5月31日。
- 参与者随机接受伊维菌素400 μg/kg每日1次连用3天(n=817)或安慰剂(n=774)。
主要发现
- 共1800例参与者被随机分组(平均[SD]年龄48[12]岁;女性932例[58.6%];753例[47.3%]报告至少接种2剂SARS-CoV-2疫苗),其中1591例完成试验。
- 恢复时间改善的风险比(HR)为1.07(95%可信区间[CrI] 0.96-1.17;后验P值[HR>1]=.91)。
- 伊维菌素组中位恢复时间为12天(IQR 11-13),安慰剂组为13天(IQR 12-14)。
- 伊维菌素组住院或死亡10例,安慰剂组9例(1.2% vs 1.2%;HR 1.1[95%CrI 0.4-2.6])。
- 最常见严重不良事件为COVID-19肺炎(伊维菌素组n=5;安慰剂组n=7)和静脉血栓栓塞(伊维菌素组n=1;安慰剂组n=5)。
关键数值与推荐
- 主要结局为持续恢复时间,定义为至少连续3天无症状。
- 7个次要结局,包括第28天住院或死亡的复合终点。
临床怎么用
- 原文结论指出,这些发现不支持在轻中度COVID-19患者中使用伊维菌素。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The effectiveness of ivermectin to shorten symptom duration or prevent hospitalization among outpatients in the US with mild to moderate symptomatic COVID-19 is unknown. OBJECTIVE: To evaluate the efficacy of ivermectin, 400 μg/kg, daily for 3 days compared with placebo for the treatment of early mild to moderate COVID-19. DESIGN, SETTING, AND PARTICIPANTS: ACTIV-6, an ongoing, decentralized, double-blind, randomized, placebo-controlled platform trial, was designed to evaluate repurposed therapies in outpatients with mild to moderate COVID-19. A total of 1591 participants aged 30 years and older with confirmed COVID-19, experiencing 2 or more symptoms of acute infection for 7 days or less, were enrolled from June 23, 2021, through February 4, 2022, with follow-up data through May 31, 2022, at 93 sites in the US. INTERVENTIONS: Participants were randomized to receive ivermectin, 400 μg/kg (n = 817), daily for 3 days or placebo (n = 774). MAIN OUTCOMES AND MEASURES: Time to sustained recovery, defined as at least 3 consecutive days without symptoms. There were 7 secondary outcomes, including a composite of hospitalization or death by day 28. RESULTS: Among 1800 participants who were randomized (mean [SD] age, 48 [12] years; 932 women [58.6%]; 753 [47.3%] reported receiving at least 2 doses of a SARS-CoV-2 vaccine), 1591 completed the trial. The hazard ratio (HR) for improvement in time to recovery was 1.07 (95% credible interval [CrI], 0.96-1.17; posterior P value [HR >1] = .91). The median time to recovery was 12 days (IQR, 11-13) in the ivermectin group and 13 days (IQR, 12-14) in the placebo group. There were 10 hospitalizations or deaths in the ivermectin group and 9 in the placebo group (1.2% vs 1.2%; HR, 1.1 [95% CrI, 0.4-2.6]). The most common serious adverse events were COVID-19 pneumonia (ivermectin [n = 5]; placebo [n = 7]) and venous thromboembolism (ivermectin [n = 1]; placebo [n = 5]). CONCLUSIONS AND RELEVANCE: Among outpatients with mild to moderate COVID-19, treatment with ivermectin, compared with placebo, did not significantly improve time to recovery. These findings do not support the use of ivermectin in patients with mild to moderate COVID-19. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04885530.
引用
- Naggie S, Boulware DR, Lindsell CJ, et al. Effect of Ivermectin vs Placebo on Time to Sustained Recovery in Outpatients With Mild to Moderate COVID-19: A Randomized Clinical Trial. JAMA. 2022. PMID: 36269852. doi:10.1001/jama.2022.18590
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。